Chimerix, Inc. (CMRX) Releases Earnings Results, Beats Estimates By $0.05 EPS

Chimerix, Inc. (NASDAQ:CMRX) issued its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.05, Bloomberg Earnings reports. The company had revenue of $0.68 million during the quarter, compared to analysts’ expectations of $1.28 million. Chimerix had a negative net margin of 1,514.27% and a negative return on equity of 24.68%.

Shares of Chimerix (NASDAQ:CMRX) traded down 1.14% on Friday, hitting $4.35. The company had a trading volume of 140,130 shares. The company has a 50 day moving average price of $4.98 and a 200 day moving average price of $5.41. The firm’s market capitalization is $204.65 million. Chimerix has a 1-year low of $3.66 and a 1-year high of $6.64.

CMRX has been the subject of several recent analyst reports. Zacks Investment Research raised Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a report on Wednesday, August 9th. FBR & Co reaffirmed a “hold” rating and set a $7.00 price target on shares of Chimerix in a report on Monday, May 1st. Cowen and Company reaffirmed a “hold” rating and set a $6.00 price target on shares of Chimerix in a report on Friday, April 28th. Finally, ValuEngine downgraded Chimerix from a “hold” rating to a “sell” rating in a report on Friday, August 11th.

Large investors have recently modified their holdings of the stock. Trexquant Investment LP bought a new stake in shares of Chimerix during the first quarter worth about $226,000. Parametric Portfolio Associates LLC increased its stake in shares of Chimerix by 11.0% in the first quarter. Parametric Portfolio Associates LLC now owns 282,948 shares of the biopharmaceutical company’s stock worth $1,805,000 after buying an additional 28,003 shares during the period. TFS Capital LLC bought a new stake in shares of Chimerix during the first quarter worth about $684,000. Teza Capital Management LLC bought a new stake in shares of Chimerix during the first quarter worth about $135,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Chimerix by 7.0% in the first quarter. Bank of New York Mellon Corp now owns 245,080 shares of the biopharmaceutical company’s stock worth $1,564,000 after buying an additional 16,117 shares during the period. Institutional investors and hedge funds own 64.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/08/19/chimerix-inc-cmrx-issues-earnings-results-updated.html.

Chimerix Company Profile

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Earnings History for Chimerix (NASDAQ:CMRX)

What are top analysts saying about Chimerix Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chimerix Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit